You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
An Interactive Informed Consent Program for Cardiac Procedures
SBC: ARCHIE MD INC. Topic: N/ADESCRIPTION (provided by applicant): Informed consent has become an essential component of the doctor-patient interaction. The informed consent process requires that patients not only be given information about proposed medical treatment, but that it be presented in an understandable way so the patient can make meaningful choices about medical alternatives. At the heart of the inf ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO
SBC: Arteriocyte, Inc. Topic: N/ADESCRIPTION (provided by applicant): The clinical significance of ocular angiogenesis is enormous, due to the fact that in the western hemisphere, retinal neovascularization resulting from diabetic retinopathy is the most common cause of new blindness in young patients, and choroidal neovascularization (CNV) resulting from AMD is the chief cause of severe and irreversible loss of vision in elderly ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Long distance nerve regeneration via processed allografts in a caprine model
SBC: Axogen Corporation Topic: N/ADESCRIPTION (provided by applicant): Every year in the US, several million people suffer serious peripheral nerve injury. Injuries to the peripheral nervous system (PNS) are a major source of disability, impairing the ability to move muscles or to feel normal sensations. To treat these problems, more than one million procedures were performed in the US in 2002, totaling more than $10 billion in me ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
User Adaptation of AAC Device Voices
SBC: BIOSPEECH INC Topic: N/ADESCRIPTION (provided by applicant): A wide range of individuals cannot communicate by voice. Voice enabled Augmentative and Alternative Communication (AAC) devices are often the only channel available by which these individuals can communicate. While many voice enabled AAC devices are currently available, they lack the important ability to generate customized speech that mimics aspects of the use ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
HUCBC modulation of Alzheimer-like pathology and behavioral changes
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Modulation of the inflammatory cascade by several diverse strategies including A immunization, non-steroidal anti-inflammatory drug (NSAID) administration, and manipulation of microglial activation states have all been shown to reduce Alzheimer disease (AD)-like pathology, and cognitive deficits in AD transgenic mouse models. Our recent study demonstrated ameli ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Designed Antimalarial Agents Overcoming Chloroquine-Resistance
SBC: DESIGNMEDIX, INC. Topic: N/ADESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address the need for an orally available and inexpensive replacement drug, we have developed a novel class of molecules called "reversed chloroquines" (RCQs) which act against both chloroquine-resistant and c ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Dynamic combinatorial chemistry for nucleic acids
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: N/ADESCRIPTION (provided by applicant): The proposed research will develop dynamic combinatorial chemistry as a new and innovative strategy to allow a DNA or RNA target in a biological sample to assemble its own template under conditions of dynamic equilibrium. This chemistry incorporates element that allows the template-created primer to primes the synthesis of a strand of DNA complementary to the t ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
MVA-based vaccines against highly pathogenic avian influenza
SBC: INVIRAGEN, LLC Topic: N/ADESCRIPTION (provided by applicant): There is an immediate need for a highly safe and efficacious vaccine that can protect against highly pathogenic avian influenza viruses (H5N1). This strain of influenza virus emerged recently in Southeastern Asia producing severe outbreaks in poultry and wildlife species and has occasionally affected humans with high mortality rates. The virus has quickly sprea ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Coping Power: Interactive Video Development
SBC: LOCHNELS Topic: N/ADESCRIPTION (provided by applicant): This Phase I project will develop comprehensive interactive video materials to enhance the outcome effects and facilitate the wide-scale dissemination of the Coping Power prevention program. Coping Power is a manualized cognitive behavioral preventive intervention with demonstrated efficacy and effectiveness for preadolescent children at-risk for substance abus ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
Combination Strategies for Anthracycline Cardiotoxicity
SBC: NOVA-THER TECHNOLOGIES Topic: N/ADESCRIPTION (provided by applicant): Despite its widespread use, the clinical utility of doxorubicin (DOX) is specifically compromised by dose-limiting cardiotoxicities. Currently approved therapy (dexrazoxane) has only modest value in adults and its usefulness in children for cardiac protection is still being investigated. Efficacy of DOX also seems to be reduced during dexrazoxane co-administrat ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health